Welcome to our dedicated page for Pulse Biosciences SEC filings (Ticker: PLSE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage disclosures can feel like a lab manual—especially when Pulse Biosciences’ Nano-Pulse Stimulation milestones, FDA submissions, and funding rounds are scattered across hundreds of SEC pages. Finding R&D costs or tracking when executives buy shares shouldn’t require a PhD.
Stock Titan’s AI reads every Pulse Biosciences annual report 10-K simplified, Pulse Biosciences quarterly earnings report 10-Q filing, and Pulse Biosciences 8-K material events explained the moment they hit EDGAR. Our platform converts technical jargon into clear summaries, flags cash-runway updates, and links clinical-trial progress to revenue outlook—so you can act before the market digests the details.
Need fast answers? Ask natural questions like “understanding Pulse Biosciences SEC documents with AI” or “Pulse Biosciences proxy statement executive compensation” and jump straight to the line items that matter. Real-time alerts surface every Pulse Biosciences insider trading Form 4 transactions, while heat-maps highlight patterns in Pulse Biosciences executive stock transactions Form 4. Our coverage spans:
- 10-K & 10-Q: cash burn, clinical spend, segment results with AI commentary
- 8-K: trial results, device clearances, leadership changes
- DEF 14A: board bios and pay packages
- Form 4: insider buys and sells—Pulse Biosciences Form 4 insider transactions real-time
Whether you’re evaluating NPS commercialization odds or scanning a Pulse Biosciences earnings report filing analysis, our AI-powered summaries, expert annotations, and instant notifications ensure Pulse Biosciences SEC filings are explained simply—so you save hours and never miss a signal.
Pulse Biosciences, Inc. (Nasdaq: PLSE) filed a Form 8-K announcing the appointment of Steven T. Weber as Vice President of Accounting & Global Corporate Controller, effective 14 Jul 2025. Weber will also assume the role of principal accounting officer, succeeding the prior incumbent (not specified in the filing). The 25-year finance veteran most recently served as SVP, Corporate Controller & PAO at IGM Biosciences and previously held senior roles at Aeglea Biotherapeutics and PwC.
Compensation & equity incentives: Weber’s cash compensation (base salary and target bonus) aligns with existing VP pay bands; specific dollar amounts were not disclosed. He received a non-statutory option for 55,000 shares at an exercise price of $16.03 (close of 11 Jul 2025). Vesting structure:
- Time-based: 27,500 shares vest 25% on the 1-year anniversary then quarterly over three additional years.
- Performance-based: up to 27,500 shares vest in four equal tranches tied to market-cap milestones of $1.5 B, $2.25 B, $3.0 B, and $4.0 B, each requiring 270 consecutive days and no earlier than year-end 2026-2029.
Weber signed standard inventions, confidentiality, non-competition and indemnification agreements. There are no related-party transactions or family relationships disclosed.
Investor takeaways: This is a governance-focused event that strengthens the finance function with a seasoned CPA. The equity package is modest (~0.2% of shares outstanding) and heavily performance-weighted, aligning Weber’s incentives with long-term shareholder value. No immediate financial impact or guidance changes were provided.
FAQ
What is the current stock price of Pulse Biosciences (PLSE)?
What is the market cap of Pulse Biosciences (PLSE)?
What is Nano-Pulse Stimulation (NPS) technology?
How does Pulse Biosciences generate revenue?
In which therapeutic areas is the technology applied?
How does the company differentiate itself from traditional therapies?
What role does research and development play in the company?
How does Pulse Biosciences ensure the safety of its technology?
How is Pulse Biosciences positioned in the competitive landscape of medical devices?
How does the technology contribute to modern healthcare?
